These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30573789)

  • 1. MRD to help assess response in CLL.
    Romero D
    Nat Rev Clin Oncol; 2019 Feb; 16(2):68. PubMed ID: 30573789
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
    [No Abstract]   [Full Text] [Related]  

  • 3. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
    Gopalakrishnan S; Wierda W; Chyla B; Menon R; Miles D; Humerickhouse R; Awni W; Salem AH; Mensing S; Freise KJ
    Clin Pharmacol Ther; 2021 Feb; 109(2):424-432. PubMed ID: 32749675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
    Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
    Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
    Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
    J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
    Vitale C; Ferrajoli A
    Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
    Wierda WG
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):214-216. PubMed ID: 31188811
    [No Abstract]   [Full Text] [Related]  

  • 10. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
    Uchiyama T; Yokoyama A; Aoki S
    J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases.
    Saburi M; Nishikawa T; Miyazaki Y; Kohno K; Sakata M; Okuhiro K; Nakayama T; Ohtsuka E; Ogata M
    J Clin Exp Hematop; 2024; 64(2):152-155. PubMed ID: 38925975
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 14. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
    Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
    [No Abstract]   [Full Text] [Related]  

  • 15. Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
    Eichhorst B; Fürstenau M; Hallek M
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):482-489. PubMed ID: 31808867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
    Nierengarten MB
    Cancer; 2024 Oct; 130(19):3237. PubMed ID: 39226085
    [No Abstract]   [Full Text] [Related]  

  • 17. CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
    Fakhri B; Andreadis C
    Oncology (Williston Park); 2019 Nov; 33(11):. PubMed ID: 31769861
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of relapsed chronic lymphocytic leukemia after venetoclax.
    Thompson MC; Mato AR
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):18-23. PubMed ID: 33275734
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
    Eradat H
    Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.